Trial Profile

A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir dipivoxil; Emtricitabine/tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Registrational; Therapeutic Use
Sponsors Gilead Sciences

29 Aug 2020 Data taken from (GS-US-174-0102, GS-US-174-0103) trials to develope ML models that identify and quantify histologic features in a clinical study of HBV patients receiving antiviral therapy presented at The International Liver Congress 2020
29 Aug 2020 Results of a pooled analysis of data pooled from 5 Phase 3 studies evaluating tenofovir based regimens to determine the associations of ALT flares with different treatment outcomes presented at The International Liver Congress 2020
09 Jun 2019 Trial has been completed in UK.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com